US Edition
Whitepaper outlines regulatory steps for low-GWP medical propellant transition
Summary by European Pharmaceutical Manufacturer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Whitepaper outlines regulatory steps for low-GWP medical propellant transition
Orbia Fluor & Energy Materials’ pharmaceutical business unit has published a new whitepaper about the industry’s ongoing transition to pressurised metered dose inhalers (pMDIs) to low global warming potential (Low-GWP) propellants.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium